Cell Therapeutics, Inc. markets lymphoma drug, Zevalin, in the United States. Zevalin is an FDA-approved radioimmunotherapeutic for treating lymphoma. The company also develops, acquires, and commercializes novel treatments for cancer. In addition, Cell Therapeutics develops XYOTAX for the treatment of non-small cell lung cancer and ovarian cancer; Pixantrone, a novel compound in the class of drugs known as anthracyclines, for non-HodgkinÂ’s lymphoma; and Brostallicin, which is in first-line Phase II study for the treatment of sarcoma. The company has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd. and PG-TXL Company, L.P. It has a joint venture with Spectrum Pharmaceuticals, Inc. to commercialize and develop Zevalin(R) in the United States. The company was founded in 1991 and is headquartered in Seattle, Washington.
The investor is willing to take risks to achieve high returns from portfolio. Investor's holding consists of speculative stocks that will produce massive gains or losses and/or the trading strategy is focused more on short term profits rather than long term appreciation
Data powered by FinancialContent.
All Rights Reserved.
Quotes delayed at least 20 minutes unless otherwise indicated.
None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.